Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from AFT Pharmaceuticals Ltd. ( (AU:AFP) ).
AFT Pharmaceuticals reported a robust financial performance for the first half of 2025, with a 33% revenue increase to $114.9 million, marking its 10th consecutive period of revenue growth. This growth was primarily driven by strong performances in Australia and a recovery in Asian and international markets. The company continues to advance its international business hubs and R&D portfolio, aiming for a $300 million revenue target by FY27. AFT’s strategic investments in licensing and development, including a novel IV iron formulation in China, position it for long-term growth and resilience.
More about AFT Pharmaceuticals Ltd.
AFT Pharmaceuticals Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of a broad range of pharmaceutical products. The company is known for its over-the-counter and prescription medicines, with a strong market presence in Australasia and expanding operations in international markets.
Average Trading Volume: 3,538
Technical Sentiment Signal: Hold
Current Market Cap: A$291.4M
For detailed information about AFP stock, go to TipRanks’ Stock Analysis page.